“Advanced therapies represent an important option in the treatment of plaque psoriasis, but as a physician, it’s critically important to continually assess if patients are having an optimal ...

In people with light skin tones, plaque psoriasis is characterized by raised ... I got ghosted for a reality TV dating show spot, and my confidence tanked. About five years ago, I was trying ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Deucravacitinib has been observed as a safe and efficacious treatment for adults with moderate to severe plaque psoriasis for up to 4 years.

New results from a subgroup analysis of the ICONIC-LEAD study showed icotrokinra was effective and safe for the treatment of moderate to severe plaque psoriasis in adolescents, according to a press ...

New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of ...

Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...

Icotrokinra appears to be an effective treatment for adolescent patients with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study. The randomized ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis, marking the company’s entry into immuno-dermatology ...